Jiangxi Synergy Pharmaceutical (300636.SZ): "Rosuvastatin" bulk drug approved by CDE.
Tonghe Pharmaceutical (300636.SZ) announced that the company recently obtained approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the registration of the raw material for "Roxadustat." Roxadustat is mainly used to treat anemia caused by chronic kidney disease (CKD), including patients undergoing dialysis and those not undergoing dialysis.
Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received notification from the National Medical Products Administration's Center for Drug Evaluation (CDE) "Raw Material Registration Information Publicity" platform, stating that the company's submission of raw material for "Roxadustat" has been approved by the CDE. Roxadustat is mainly used for treating anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.
Related Articles
On June 16, 7ROAD (00797) spent 17.0764 million Hong Kong dollars to repurchase 14.95 million shares.
UBOX ONLINE (02429) spent HK$182,700 to repurchase 81,000 shares on June 16th.
DC Holdings made an appearance at the 2026 Cross-border E-commerce Development Conference, empowering brands to go global with their "Supply Chain AI Control Tower".
On June 16, 7ROAD (00797) spent 17.0764 million Hong Kong dollars to repurchase 14.95 million shares.
UBOX ONLINE (02429) spent HK$182,700 to repurchase 81,000 shares on June 16th.
DC Holdings made an appearance at the 2026 Cross-border E-commerce Development Conference, empowering brands to go global with their "Supply Chain AI Control Tower".
RECOMMEND
